^
Association details:
| Biomarker: | HER-2 positive |
|---|---|
| Cancer: | Gastric Cancer |
| Drug: | Herceptin (trastuzumab) (HER2 inhibitor) + AiRuiKa (camrelizumab) (PD1 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
A Study of the Advanced Adenocarcinoma of Stomach and Gastroesophageal Junction With Camrelizumab+SOX Control Camrelizumab+SOX+ Trastuzumab
Excerpt:
...- 1) Age 18-75 years old; Male or female; 2) Histopathological examination of gastroscopy biopsy confirmed adenocarcinoma of stomach and gastroesophageal junction; 3) Imaging (CT/MRI) and ultrasonic gastroscopy confirmed that: cT≥T2 and/or regional lymph node positive (N+); 4)HER-2 positive is the test result of IHC3+ or IHC2+/FISH+, and HER-2 test score standard refers to her-2 test guide for gastric cancer; 5)...
Trial ID:
Source:
Title:
Camrelizumab combined with trastuzumab and CapeOX in HER2-positive patients with advanced gastric cancer in the first-line setting: an single-arm, monocentric phase 2 trial
Excerpt:
......
Trial ID:
Less C2 evidence
Source:
Title:
Phase II study of SHR1210 and trastuzumab in combination with CAPOX for neoadjuvant treatment of HER2-positive gastric or gastroesophageal junction (GEJ) adenocarcinoma.
Published date:
01/18/2022
Excerpt:
In this ongoing, single-arm, phase II study...with histopathologically diagnosed resectable HER2-positive gastric or GEJ adenocarcinoma who had clinical T3/N+ or higher stage. Neoadjuvant combination of SHR1210, transtuzumab and CAPOX is a safe and efficacious treatment option for patients with HER2-positive gastric or GEJ adenocarcinoma.
Secondary therapy:
CAPOX
DOI:
10.1200/JCO.2022.40.4_suppl.296
Trial ID:
